• Alphabet (NasdaqGS:GOOGL) subsidiaries Waymo and Isomorphic Labs are pursuing major new funding moves in autonomous driving and AI drug discovery.

• Waymo has lined up US$5b in debt financing to support an international expansion of its robotaxi operations outside the US.

• Isomorphic Labs is reported to be targeting a US$40b to US$50b valuation in its next capital raise focused on AI driven drug design.

• Waymo’s US$5b financing and Isomorphic Labs’ targeted US$40b to US$50b valuation merit weighing alongside the rest of our Alphabet work. We have also spotted 2 warning signs (2 major) worth knowing about at Alphabet.

For readers who want more ideas around the picks and shovels behind AI, the next stop is 92 AI infrastructure stocks.

Alphabet runs a broad mix of digital services across regions including the US, Europe and Asia-Pacific, so moves in areas like robotaxis and AI driven drug discovery show how management is trying to extend its existing technology and data capabilities into new commercial arenas.

See how Alphabet’s balance sheet measures up.

What Waymo’s loan and Isomorphic’s valuation signal for Alphabet’s AI spending story

The Alphabet Narrative rests on a simple trade off. Heavy AI and data center spending only makes sense if it converts into solid demand for Gemini, Google Cloud and adjacent bets like robotaxis and AI drug discovery.

“The main factor that has to go right is that Alphabet converts heavy AI infrastructure and data center investment, including custom TPUs and long-term power contracts, into durable and profitable demand for Gemini and Google Cloud…”

See how the full story points towards a $429 fair value for Alphabet.

Waymo’s US$5b term loan pushes more of that AI buildout onto subsidiary-level borrowing rather than Alphabet’s own cash, which can help financial flexibility if free cash flow is already tight. It also adds fixed obligations to a capital intensive project where timelines and regulatory paths are less clear than core Search or Cloud. Compared with rivals like Tesla or Uber that lean more on partnerships or asset light models, this is a more balance-sheet-heavy way to pursue autonomous driving.

Isomorphic Labs pursuing a US$40b to US$50b valuation highlights how far Alphabet is willing to stretch its AI ambitions beyond advertising and enterprise software. High pricing for a still early stage drug discovery platform leans into the reward side of the Narrative around future AI monetisation, while also magnifying the existing risk analysts flag around capital intensity and non cash earnings. Depending on whether you think these units eventually justify their funding, the same headlines can read as efficient leverage of Alphabet’s AI stack or as extra strain on an already demanding investment plan.